Curated News
By: NewsRamp Editorial Staff
July 29, 2026
BRAIN Biotech Appoints Dr. Sven K. Weber as Future CEO
TLDR
- New CEO Dr. Sven K. Weber, with proven expertise in enzyme business, aims to accelerate growth and profitability at BRAIN Biotech.
- Dr. Weber will succeed Adriaan Moelker as CEO on October 1, 2026, transitioning smoothly with Moelker staying as senior advisor until January 2027.
- The leadership transition ensures continuity and innovation at BRAIN Biotech, fostering development of sustainable biological solutions for a better future.
- Dr. Weber previously led BASF's global enzyme business, driving innovation and revenue growth before joining BRAIN Biotech as CEO.
Impact - Why it Matters
This leadership change matters because it signals a strategic shift for BRAIN Biotech as it aims to accelerate growth and profitability in the competitive specialty enzyme market. Dr. Weber’s proven track record at BASF in driving innovation-led growth suggests that BRAIN may introduce new products and expand its market presence, potentially benefiting customers and investors. The smooth succession ensures continuity while fresh expertise could lead to faster commercialization of biotechnological solutions, impacting industries from food to life sciences.
Summary
BRAIN Biotech AG Announces CEO Succession: Dr. Sven K. Weber to Take Helm in 2026
ZWINGENBERG, GERMANY - The Supervisory Board of BRAIN Biotech AG (“BRAIN”) has appointed Dr. Sven K. Weber as the future CEO, effective October 1, 2026. Dr. Weber, who brings extensive experience from BASF Group, will succeed Adriaan Moelker, who will retire at the end of his contract term after six years of leadership. Mr. Moelker will remain as a senior advisor until January 2027. This transition marks a strategic move for BRAIN Biotech, a leader in specialty enzymes and bioprocess solutions.
Dr. Sven K. Weber, 44, has held several leadership roles at BASF since 2011, most recently as Vice President of the Global Business Unit Feed Enzymes & Feed Performance Ingredients. In this role, he drove innovation-led growth and significantly increased revenue and earnings. His background includes managing the global automotive OEM business at Chemetall GmbH and heading contract research at hte GmbH. Dr. Weber holds a diploma and doctorate in chemistry from the University of Heidelberg and completed an executive program at SGMI Management Institute in St. Gallen. His appointment signals BRAIN’s commitment to accelerating growth and strengthening its position in the industrial enzyme market.
Dr. Michael Majerus, Chairman of the Supervisory Board, expressed gratitude to Mr. Moelker for repositioning BRAIN as an integrated manufacturing company and successfully monetizing projects from the BRAINBioIncubator. He highlighted Dr. Weber’s international experience and expertise in industrial enzymes, which will be crucial for executing the company’s strategic direction and tapping into new growth opportunities. Dr. Weber himself emphasized his intention to build on BRAIN’s strong technological foundation, accelerate growth, and bring innovative products to market faster. The company, listed on the Frankfurt Stock Exchange, generated €49.6 million in revenue in the 2024/25 fiscal year with around 280 employees. For more details, visit the original release on NEWMEDIAWIRE.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, BRAIN Biotech Appoints Dr. Sven K. Weber as Future CEO
